Norland's heel bone density test cleared:
This article was originally published in Clinica
The FDA has cleared Norland Medical Systems' new peripheral bone density measuring device which takes density readings at the heal. The portable Apollo DXA device will cost less than $20,000 and will be marketed at physicians' offices in the US. The company has struck a deal with Tokai Financial Services under which Tokai will provide financing for purchasers of the device.
You may also be interested in...
An upturn in M&A activity across the whole healthcare sector is expected in 2021, with the COVID-19 pandemic and the associated development of a vaccine shining a light on the sector, says a recent survey by Jefferies.
Australian patients with phototoxicity due to the rare condition EPP will now have their first treatment option – provided the drug's developer, Clinuvel, secures reimbursement under the Pharmaceutical Benefits Scheme.
Roche has partnered with Regeneron and Atea, but the company continues to leverage its long legacy in infectious diseases to identify good treatment options for the novel coronavirus.